121 related articles for article (PubMed ID: 36646410)
21. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
22. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
[TBL] [Abstract][Full Text] [Related]
23. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity.
Mathias RA; Greco TM; Oberstein A; Budayeva HG; Chakrabarti R; Rowland EA; Kang Y; Shenk T; Cristea IM
Cell; 2014 Dec; 159(7):1615-25. PubMed ID: 25525879
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
26. High incidence of PI3K pathway gene mutations in South Indian cervical cancers.
Rose MM; Dhamodharan S; Revathidevi S; Chakkarappan SR; Jagadeesan MG; Subbiah S; Nakaoka H; Inoue I; Murugan AK; Munirajan AK
Cancer Genet; 2022 Jun; 264-265():100-108. PubMed ID: 35568000
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.
Mori R; Ishiguro H; Kimura M; Mitsui A; Sasaki H; Tomoda K; Mori Y; Ogawa R; Katada T; Kawano O; Harada K; Fujii Y; Kuwabara Y
J Surg Res; 2008 Apr; 145(2):320-6. PubMed ID: 18262558
[TBL] [Abstract][Full Text] [Related]
28. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
29. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
30. SIRT4 prevents excitotoxicity via modulating glutamate metabolism in glioma cells.
Yalçın GD; Colak M
Hum Exp Toxicol; 2020 Jul; 39(7):938-947. PubMed ID: 32081049
[TBL] [Abstract][Full Text] [Related]
31. Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source.
Foster R; Griffin S; Grooby S; Feltell R; Christopherson C; Chang M; Sninsky J; Kwok S; Torrance C
PLoS One; 2012; 7(9):e45061. PubMed ID: 23028762
[TBL] [Abstract][Full Text] [Related]
32. SIRT4 suppresses the PI3K/Akt/NF‑κB signaling pathway and attenuates HUVEC injury induced by oxLDL.
Tao Y; Yu S; Chao M; Wang Y; Xiong J; Lai H
Mol Med Rep; 2019 Jun; 19(6):4973-4979. PubMed ID: 31059091
[TBL] [Abstract][Full Text] [Related]
33. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
36. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
38. HepaCAM‑PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.
He Z; Gao Y; Li T; Yu C; Ou L; Luo C
Int J Oncol; 2022 Apr; 60(4):. PubMed ID: 35191516
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
